The Profile of Osteogenesis Imperfecta in Dr. Moewardi General Hospital Year 2020-2021: A Retrospective Study

Authors

  • Udi Heru Nefihancoro Department of Orthopaedic and Traumatology Faculty of Medicine Universitas Sebelas Maret
  • Ricat Hinaywan Malik Department of Orthopaedic and Traumatology Faculty of Medicine Universitas Sebelas Maret

DOI:

https://doi.org/10.21776/ub.jkb.2023.032.04.6

Keywords:

Bisphosphonate, epidemiology, osteogenesis imperfecta, signs, surgery, symptoms

Abstract

Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by bone fragility and long bone deformities. This study aims to report the profile of osteogenesis imperfecta in Dr. Moewardi General Hospital. The patients were searched from the medical record, registered from January 1, 2020, to December 31, 2021, in Dr. Moewardi General Hospital, a tertiary hospital in Surakarta, Indonesia. The data were recorded and described in tables as age, sex, type of OI according to Sillence, clinic, ward admission, signs and symptoms, bisphosphonate therapy and its discipline, as well as the surgical/non-surgical treatment. The quantity of male patients is higher than that of females, OI type IV is the most common, the most common sign/symptoms are fracture and blue sclera, and the most common bone to be fractured is the femur. More than half of patients received bisphosphonate therapy, but only a quarter received it routinely. More than half of patients have performed surgery as the treatment of fractures. Osteogenesis imperfecta patients require an interdisciplinary and tailored treatment that involves both medical and surgical components.

Downloads

Download data is not yet available.

References

Burtsev ME, Frolov AV, Logvinov AN, Ilyin DO, and Korolev AV. Current Approach to Diagnosis and Treatment of Children with Osteogenesis Imperfecta. Pediatric Traumatology, Orthopaedics, and Reconstructive Surgery. 2019; 7(2): 87-102.

Lim J, Grafe I, Alexander S, and Lee B. Genetic Causes and Mechanisms of Osteogenesis Imperfecta. Bone. 2017; 102: 40-49.

Folkestad L, Hald JD, Ersbøll AK, et al. Fracture Rates and Fracture Sites in Patients with Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. Journal of Bone and Mineral Research. 2017; 32(1): 125-134.

Sillence DO, Senn A, and Danks DM. Genetic Heterogeneity in Osteogenesis Imperfecta. Journal of Medical Genetics. 1979; 16(2): 101-116.

Marini JC, Forlino A, Bachinger HP. Osteogenesis Imperfecta. Nature Reviews Disease Primers. 2017; 3: 17052.

Ignatovich ON, Namazova-Baranova LS, Margieva TV, et al. Osteogenesis Imperfecta: Diagnostic Feature. Pediatric Pharmacology. 2018; 15(3): 224-232.

Lindahl K, Astrom E, Rubin CJ, et al. Genetic Epidemiology, Prevalence, and Genotype–Phenotype Correlations in the Swedish Population with Osteogenesis Imperfecta. European Journal of Human Genetics. 2015; 23(8): 1042-1050.

Martin E and Shapiro JR. Osteogenesis Imperfecta: Epidemiology and Pathophysiology. Current Osteoporosis Reports. 2007; 5(3): 91-97.

Etich J, Leßmeier L, Rehberg M, et al. Osteogenesis Imperfecta—Pathophysiology and Therapeutic Options. Molecular and Cellular Pediatrics. 2020; 7: 1-9.

Zhytnik L, Maasalu K, Duy BH, et al. IFITM5 Pathogenic Variant Causes Osteogenesis Imperfecta V with Various Phenotype Severity in Ukrainian and Vietnamese Patients. Human Genomics. 2019; 13: 1-11.

Goudriaan WA, Harsevoort GJ, van Leeuwen M, Franken AA, and Janus GJM. Incidence and Treatment of Femur Fractures in Adults with Osteogenesis Imperfecta: An Analysis of an Expert Clinic of 216 Patients. European Journal of Trauma and Emergency Surgery. 2020; 46(1): 165-171.

Storoni S, Treurniet S, Maugeri A, et al. Prevalence and Hospital Admissions in Patients with Osteogenesis Imperfecta in the Netherlands: A Nationwide Registry Study. Frontiers in Endocrinology (Lausanne). 2022; 13: 1-7.

Rauch F, Travers R, Parfitt A, and Glorieux F. Static and Dynamic Bone Histomorphometry in Children with Osteogenesis Imperfecta. Bone. 2000; 26(6): 581-589.

Dwan K, Phillipi CA, Steiner RD, and Basel D. Bisphosphonate Therapy for Osteogenesis Imperfecta. Cochrane Database of Systematic Reviews. 2016; 2016: 1-58.

Ruggiero A, Triarico S, Romano A, Maurizi P, Attina G, and Mastrangelo S. Bisphosphonates: From Pharmacology to Treatment. Biomedical &Pharmacology Journal. 2023; 16(1): 221-229.

Hastopraja R and Nasution MS. Osteogenesis Imperfecta: A Case Report. Journal of Endocrinology, Tropical Medicine, and Infectious Disease. 2022; 4(2): 50-55.

Perea SH and Green DW. Osteogenesis Imperfecta: Treatment and Surgical Management. Current Opinion in Pediatrics. 2021; 33(1): 74-78.

Harrington J, Sochett E, and Howard A. Update on the Evaluation and Treatment of Osteogenesis Imperfecta. Pediatric Clinics of North America. 2014; 61(6): 1243-1257.

Cho TJ, Ko JM, Kim H, Shin HI, Yoo WJ, and Shin CH. Management of Osteogenesis Imperfecta: A Multidisciplinary Comprehensive Approach. Clinics of Orthopedic Surgery. 2020; 12(4): 417-429.

Downloads

Published

2023-08-31

Issue

Vol. 32 No. 4 (2023)

Section

Research Article

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).